{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-001504","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.565632+00:00","generated_at":"2026-05-15T12:55:25.999892+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harvard Bioscience 2025 revenue $86.6M, net loss $56.7M incl $48M goodwill impairment; permanent CFO appointed","bullets":["Q4 revenue $23.7M (down from $24.6M YoY); gross margin 59.7% (up from 57.1%).","Full-year net loss $56.7M driven by $48.0M goodwill impairment in Q1 2025.","Adjusted EBITDA $8.1M for FY2025 vs $7.2M in FY2024; operating cash flow $6.7M vs $1.4M.","Interim CFO Mark Frost appointed permanent CFO effective March 12, 2026.","Introduced FY2026 guidance for revenue growth from new translational science products; no specific figures provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-001504","json":"https://secwatch.observer/filing/0001171843-26-001504.json","markdown":"https://secwatch.observer/filing/0001171843-26-001504.md","text":"https://secwatch.observer/filing/0001171843-26-001504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326001504/0001171843-26-001504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326001504/f8k_031226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:55:25.999892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1045735368b9f250dd429bf5a7d832e2ace2ab4b","claim":"HARVARD BIOSCIENCE INC reported financial results for three and twelve months ended December 31, 2025.","evidence_excerpt":"On March 12, 2026, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the three and twelve months ended December 31, 2025, and the details of a related conference call to be held at 8:00 AM ET on March 12, 2026. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326001504/0001171843-26-001504-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and twelve months ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}